TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB | Market Closed - Deutsche Boerse AG 15:40:34 2024-06-21 EDT | ||
| 7.12 EUR | -1.79% |
|
| Current month | +33.83% | ||
| 1 month | +58.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 7.12 | -1.79% |
| 24-06-20 | 7.25 | -7.53% |
| 24-06-19 | 7.84 | +11.68% |
| 24-06-18 | 7.02 | -2.09% |
| 24-06-17 | 7.17 | +6.38% |
Delayed Quote Deutsche Boerse AG
Last update June 21, 2024 at 03:40 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW88XY |
| ISIN | DE000SW88XY8 |
| Date issued | 2024-04-19 |
| Strike | 2,331 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.63 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.9 € |
|---|---|
| Lowest since issue | 3.74 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,806
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.43%
- Stock Market
- Certificates
- Certificat
